{
  "researcher": "Weaver, Donald F",
  "project": "Design and Development of Brain Permeant Indoleamine-2,3-Dioxygenase Inhibitors",
  "grant_code": "201709PJT",
  "grant_date": "2017-09",
  "data": {
    "primary_institute": "Neuroinflammation and Neurodegenerative Diseases",
    "level1_ip": [
      {
        "title": "Inhibitor Of Indoleamine 2,3-dioxygenase-1 And Methods Of Manufacture And Use Thereof",
        "type": "patent",
        "filing_year": 2021,
        "assignee": "Donald F. Weaver et al.",
        "description": "Patent application for brain-permeant IDO1 inhibitors relevant to neurological and cancer therapies."
      },
      {
        "title": "Indoleamine 2,3 dioxygenase inhibitors and applications",
        "type": "patent",
        "filing_year": 2018,
        "assignee": "Donald F. Weaver et al.",
        "description": "Patent covering IDO1 inhibitors with brain permeability and therapeutic applications."
      }
    ],
    "level2_companies": [
      {
        "company_name": "Neurochem Inc.",
        "founding_year": 1990,
        "industry": "Biotechnology - Alzheimer's therapeutics",
        "connection": "Co-founded by Donald F. Weaver; develops drugs for Alzheimer's disease including related neuroinflammation pathways."
      },
      {
        "company_name": "Treventis Corp.",
        "founding_year": 2015,
        "industry": "Biotechnology - Neurodegenerative therapeutics",
        "connection": "Co-founded by Donald F. Weaver; focuses on small molecule therapeutics targeting tau pathology in Alzheimer's disease."
      }
    ],
    "level5_exits": [
      {
        "company_name": "Neurochem Inc.",
        "exit_type": "IPO",
        "exit_year": 2017,
        "value": "Publicly listed on TSX and NASDAQ",
        "acquirer": ""
      }
    ]
  },
  "scores": {
    "level1": 2,
    "level2": 2,
    "level5": 1,
    "total": 5,
    "highest_level": 5
  }
}